Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Idacio (Adalimumab Biosimilar) Auto-injector vs Pre-filled Syringe
NCT04018599Phase 1Completed
- Sponsor
- Fresenius Kabi
- Start
- Jul 2019
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA) and 6 more (2 arms), sponsored by Fresenius Kabi. Primary endpoints: Area Under the Concentration-time Curve from Time Zero to Infinity, Maximum Observed Plasma Concentration and 1 more. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)juvenile idiopathic arthritis (JIA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)Crohn's disease
Beyond the preview
Go deeper on NCT04018599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04018599.